Therapy of locally advanced pancreatic adenocarcinoma: Unresectable and borderline patients

Expert Review of Anticancer Therapy

Volumn 11, Issue 10, 2011, Pages 1555-1565

  Kircher, Sheetal M ^a   Krantz, Seth B ^b   Nimeiri, Halla S ^a,b   Mulcahy, Mary F ^a,b   Munshi, Hidayatullah G ^a,b,c   Benson, Al B ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

borderline resectable; epithelial mesenchymal transition; gemcitabine; neoadjuvant chemotherapy; pancreatic cancer

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TIPIFARNIB;

ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATICODUODENECTOMY; RADIATION RESPONSE; REVIEW; SEPSIS; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

EID: 80054769170     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.125     Document Type: Review

References (72)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin. 60, 277-300 (2010).
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. Surg. 165(1), 68-72; discussion 72-63 (1993).
3. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 4(6), 567-579 (2000).
4. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William TLW, Linehan DC. Pretreatment assessment of resectable and borderline-resectable pancreatic cancer: expert consensus statement. Ann. Surg. Oncol. 16(7), 1727-1733 (2009).
5. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59(12), 2006-2010 (1987).
6. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fuorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 230(6), 776-782; discussion 782-774 (1999).
7. Neoptolemos JP, Dunn JA, Stocken DD et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358(9293), 1576-1585 (2001). (Pubitemid 33101907)
8. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 120(8), 899-903 (1985). (Pubitemid 15040883)
9. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350(12), 1200-1210 (2004). (Pubitemid 38339364)
10. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur. J. Cancer 29A(5), 698-703 (1993). (Pubitemid 23077048)
11. Takada T, Amano H, Yasuda H et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A Phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95(8), 1685-1695 (2002).
12. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fuorouracil therapy after curative resection in cases of pancreatic cancer. Jpn. J. Clin. Oncol. 36(3), 159-165 (2006).
13. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3), 267-277 (2007). (Pubitemid 46143304)
14. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fuorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10), 1073-1081 (2010).
15. Roldan GE, Gunderson LL, Nagorney DM et al. External beam versus intraoperative and External-beam irradiation for locally advanced pancreatic cancer. Cancer 61(6), 1110-1116 (1988). (Pubitemid 18078599)
16. Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fuorouracil), and high dose radiation + 5-fuorouracil: The Gastrointestinal Tumor Study Group. Cancer 48(8), 1705-1710 (1981). (Pubitemid 11022870)
17. Cohen SJ, Dobelbower R Jr, Lipsitz S et al. A randomized Phase III study of radiotherapy alone or with 5-fuorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int. J. Radiat. Oncol. Biol. Phys. 62(5), 1345-1350 (2005). (Pubitemid 40982053)
18. Sultana A, Tudur Smith C, Cunningham D et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br. J. Cancer 96(8), 1183-1190 (2007). (Pubitemid 46625082)
19. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J. Clin. Oncol. 21(18), 3409-3414 (2003). (Pubitemid 46594073)
20. Saif MW, Eloubeidi MA, Russo S et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J. Clin. Oncol. 23(34), 8679-8687 (2005). (Pubitemid 46211511)
21. Schneider BJ, Ben-Josef E, McGinn CJ et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 63(5), 1325-1330 (2005). (Pubitemid 41628025)
22. Vaishampayan UN, Ben-Josef E, Philip PA et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int. J. Radiat. Oncol. Biol. Phys. 53(3), 675-679 (2002). (Pubitemid 34626506)
23. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin. Oncol. 24(2 Suppl. 7), S7-S24; S27-S28 (1997).
24. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical beneft with gemcitabine as frst-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997). (Pubitemid 27251144)
25. Wolff RA, Evans DB, Gravel DM et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin. Cancer Res. 7(8), 2246-2253 (2001). (Pubitemid 32751621)
26. Blackstock AW, Bernard SA, Richards F et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J. Clin. Oncol. 17(7), 2208-2212 (1999). (Pubitemid 29318854)
27. Joensuu TK, Kiviluoto T, Karkkainen P et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 60(2), 444-452 (2004). (Pubitemid 39233463)
28. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int. J. Gastrointest. Cancer 34(2-3), 107-116 (2003). (Pubitemid 39279726)
29. Talamonti MS, Small W Jr, Mulcahy MF et al. A multi-institutional Phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann. Surg. Oncol. 13(2), 150-158 (2006). (Pubitemid 43157408)
30. Crane CH, Abbruzzese JL, Evans DB et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fuorouracil-based chemoradiation in locally advanced pancreatic cancer? Int. J. Radiat. Oncol. Biol. Phys. 52(5), 1293-1302 (2002). (Pubitemid 34302881)
31. Talamonti MS, Catalano PJ, Vaughn DJ et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fuorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J. Clin. Oncol. 18(19), 3384-3389 (2000).
32. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23(15), 3509-3516 (2005).
33. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22(8), 1430-1438 (2004). (Pubitemid 41103625)
34. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22(18), 3776-3783 (2004). (Pubitemid 41095218)
35. Conroy T, Desseigne F, Ychou M et al. Randomized Phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as frst-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 Trial. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
36. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fuorouracil alone with radiation plus concurrent and maintenance 5-fuorouracil-an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 3(3), 373-378 (1985). (Pubitemid 15132005)
37. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J. Can. Assoc. Radiol. 32(3), 164-165 (1981) (Pubitemid 12231867)
38. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J. Natl Cancer Inst. 80(10), 751-755 (1988).
39. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Defnitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol. 19(9), 1592-1599 (2008).
40. Loehrer PJ PM. A randomized Phase III study of gemcitabine in comination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 4506).
41. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J. Clin. Oncol. 27(13), 2269-2277 (2009).
42. Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J. Clin. Oncol. 25(3), 326-331 (2007). (Pubitemid 350003022)
43. Krishnan S, Rana V, Janjan NA et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal beneft from consolidative chemoradiation therapy. Cancer 110(1), 47-55 (2007). (Pubitemid 46986417)
44. Willett CG, Lewandrowski K, Warshaw AL, Efrd J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann. Surg. 217(2), 144-148 (1993). (Pubitemid 23059285)
45. Cameron JL, Crist DW, Sitzmann JV et al. Factors infuencing survival after pancreaticoduodenectomy for pancreatic cancer. Am. J. Surg. 161(1), 120-124; discussion 124-125 (1991).
46. Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA. Neoadjuvant therapy for resectable pancreatic cancer. Surg. Oncol. Clin. N. Am. 13(4), 639-661, ix (2004).
47. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26(312), 638-648 (1953).
48. Ishikawa O, Ohigashi H, Imaoka S et al. Concomitant beneft of preoperative irradiation in preventing pancreas fstula formation after pancreatoduodenectomy. Arch. Surg. 126(7), 885-889 (1991).
49. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7(4), e1000267 (2010).
50. Katz MH, Pisters PW, Evans DB et al. Borderline-resectable pancreatic cancer: the importance of this emerging stage of disease. J. Am. Coll. Surg. 206(5), 833-846; discussion 846-848 (2008).
51. Ammori JB, Colletti LM, Zalupski MM et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J. Gastrointest. Surg. 7(6), 766-772 (2003). (Pubitemid 37103131)
52. Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J. Surg. 28(10), 1011-1018 (2004). (Pubitemid 40109886)
53. Landry J, Catalano PJ, Staley C et al. Randomized Phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fuorouracil, and cisplatin followed by radiotherapy and 5-fuorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J. Surg. Oncol. 101(7), 587-592 (2010).
54. Brunner TB, Grabenbauer GG, Meyer T, Golcher H, Sauer R, Hohenberger W. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised Phase II study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 7, 41 (2007).
55. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007). (Pubitemid 46972777)
56. Kulke MH, Blaszkowsky LS, Ryan DP et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J. Clin. Oncol. 25(30), 4787-4792 (2007). (Pubitemid 350086482)
57. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J. Clin. Oncol. 28(22), 3605-3610 (2010).
58. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28(22), 3617-3622 (2010).
59. Philip PA, Mooney M, Jaffe D et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin. Oncol. 27(33), 5660-5669 (2009).
60. Wang Z, Li Y, Kong D et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the Notch signaling pathway. Cancer Res. 69(6), 2400-2407 (2009).
61. Shah AN, Summy JM, Zhang J, Park S, Parikh N, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 14(12), 3629-3637 (2007). (Pubitemid 350160137)
62. Arumugam T, Ramachandran V, Fournier KF et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69(14), 5820-5828 (2009).
63. Buck E, Eyzaguirre A, Barr S et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther. 6(2), 532-541 (2007). (Pubitemid 46332455)
64. Rasheed ZA, Yang J, Wang Q et al. Prognostic signifcance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl Cancer Inst. 102(5), 340-351 (2010).
65. Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell. Biol. 10(5), 593-601 (2008). (Pubitemid 351627379)
66. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8(6), 843-852 (2009).
67. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457-1461 (2009).
68. Drengler RL, Wood TE, Borad MJ et al. Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
69. Gupta PB, Onder TT, Jiang G et al. Identifcation of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4), 645-659 (2009).
70. Kim HJ, Czischke K, Brennan MF et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J. Gastrointest. Surg. 6(5), 763-769 (2002). (Pubitemid 40433496)
71. Massucco P, Capussotti L, Magnino A et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann. Surg. Oncol. 13(9), 1201-1208 (2006). (Pubitemid 44440421)
72. Stokes JB, Nolan NJ, Stelow EB et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann. Surg. Oncol. 18(3), 619-627 (2011).